This diagnostic odyssey for patients with ovarian cancer frequently results in a series of clinical tests, including transvaginal ultrasound (TVU) and blood-based biomarker testing including cancer antigen 125 (CA125) levels, often repeated over several months of “watch and wait.” Meanwhile, fast-growing early-stage ovarian cancer tumors [including the most common form, high-grade serous (HGS)] can double in size every 4 months, and late-stage (III/IV) tumors can double in size every 2.5 months (8). The gene discussed is MUC16; the disease is ovarian cancer.